Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922932 · ClinicalTrials.gov registry record
WF and PR OCTA in Diabetic Retinopathy
A clinical trial of Diabetic Retinopathy, sponsored by Oregon Health and Science University.
- Active
- Registry status
- 290
- Enrollment target
- 1
- Study location
NCT03922932 is a study of Diabetic Retinopathy that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 290 participants, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03922932, a study of Diabetic Retinopathy, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- 290 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans. Capillary damage from hyperglycemia causes vision loss through downstream effects, such as retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment with laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections can minimize morbidity. In the last decade, clinicians have been able to use objective structural data from optical coherence tomography (OCT) to guide the treatment of diabetic macular edema. Other aspects of care, however, still largely depend on subjective interpretation of clinical features and fluorescein angiography (FA) to determine the disease severity and treatment threshold. The recently developed OCT angiography (OCTA) provides dye-less, injection-free, three-dimensional images of the retinal and choroidal circulation with high capillary contrast. Not only is it safer, faster, and less expensive than conventional dye-based angiography, OCTA provides the potential of giving clinicians objective tools for determining severity of disease by detecting and quantifying NV and non-perfusion.
Conditions Studied
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922932
The ClinicalTrials.gov registry entry for NCT03922932 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (83% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 0 interventions.
NCT03922932 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03922932 about?
NCT03922932 is a clinical study titled "WF and PR OCTA in Diabetic Retinopathy". Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans. Capillary damage from hyperglycemia causes vision loss through downstream effects, such as retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment with laser photocoagulation and...
What is the current status of trial NCT03922932?
This trial is currently active not recruiting. The enrollment target is 290 participants. The study started on 2017-08-30. Estimated completion is 2027-12.
What conditions does trial NCT03922932 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
Who is sponsoring clinical trial NCT03922932?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922932 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.